ATNM (Actinium Pharmaceuticals) Beginning Cash Position: $48.33 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATNM Actinium Pharmaceuticals Inc ATNM
11 GF Score
Price $0.85
! 4 Warning Signs
View Full Analysis

What is Actinium Pharmaceuticals Beginning Cash Position?

Actinium Pharmaceuticals ATNM -0.65% 11 Beginning Cash Position is $48.33 Mil as of Mar. 2026. GuruFocus rates ATNM with a GF Score™ of 11/100. The stock has 4 warning signs investors should review.

Actinium Pharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2026 was $48.33 Mil.

Actinium Pharmaceuticals's quarterly Beginning Cash Position declined from Sep. 2025 ($60.26 Mil) to Dec. 2025 ($53.63 Mil) and declined from Dec. 2025 ($53.63 Mil) to Mar. 2026 ($48.33 Mil).

Actinium Pharmaceuticals's annual Beginning Cash Position declined from Dec. 2023 ($109.61 Mil) to Dec. 2024 ($76.99 Mil) and declined from Dec. 2024 ($76.99 Mil) to Dec. 2025 ($73.23 Mil).

Actinium Pharmaceuticals Beginning Cash Position Related Terms

Actinium Pharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Actinium Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Actinium Pharmaceuticals Beginning Cash Position Chart

Actinium Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.00 78.22 109.61 76.99 73.23

Actinium Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 73.23 65.65 60.26 53.63 48.33
ATNM
11GF Score
Actinium Pharmaceuticals Inc ATNM
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Actinium Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $48.33 Mil mean?
Actinium Pharmaceuticals (ATNM) has a Beginning Cash Position of $48.33 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Actinium Pharmaceuticals and its competitors.
Is Actinium Pharmaceuticals' Beginning Cash Position too high?
Actinium Pharmaceuticals' current Beginning Cash Position is $48.33 Mil. Overall, Actinium Pharmaceuticals has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Actinium Pharmaceuticals' Beginning Cash Position compare to PSTV and IGC?
Actinium Pharmaceuticals' Beginning Cash Position of $48.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Actinium Pharmaceuticals and its competitors. Actinium Pharmaceuticals's current Beginning Cash Position is $48.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Actinium Pharmaceuticals stock overvalued right now?
Actinium Pharmaceuticals (ATNM) has a current Beginning Cash Position of $48.33 Mil. The current Beginning Cash Position is $48.33 Mil. Actinium Pharmaceuticals' overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Actinium Pharmaceuticals (ATNM), the current Beginning Cash Position is $48.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Actinium Pharmaceuticals Business Description

Other Exchanges 7AY1:Germany
Address 100 Park Avenue, 23rd Floor, New York, NY, USA, 10017
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.
11GF Score

Get the complete analysis for ATNM

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.85
Price